Mercado de tratamento de distúrbios do sono no Médio Oriente e África, por tipo (insónia, apneia do sono, síndrome das pernas inquietas (RLS), narcolepsia e outros), tratamento (terapia farmacológica, terapia mecânica, dispositivos de avanço mandibular, estimulador do nervo hipoglosso, cirurgia e outros) Via de Administração (Oral, Parentérica e Outros), Tipo de Medicamento (Marca e Genéricos), Tipo de População (Crianças e Adultos), Utente Final (Hospitais, Clínicas Especializadas, Assistência Médica Domiciliária, Bloco Operatório Ambulatório e Outros), Canal de Distribuição (Concurso Directo, Farmácia hospitalar, farmácia de retalho, farmácia on-line e outras), país (África do Sul, Arábia Saudita, Emirados Árabes Unidos, Egipto, Kuwait, Israel, resto do Médio Oriente e África), tendências e previsões do setor até 2028
Análise de mercado e insights: Mercado de tratamento de distúrbios do sono no Médio Oriente e África
Espera-se que o mercado de tratamento de distúrbios do sono ganhe crescimento de mercado no período previsto de 2021 a 2028. A Data Bridge Market Research analisa que o mercado está a crescer com um CAGR de 7,0% no período previsto de 2021 a 2028 e prevê-se que atinja os 372,83 milhões de USD até 2028. O aumento da prevalência de distúrbios do sono, como a apneia do sono, insónia e narcolepsia em todo o mundo está a impulsionar o mercado de tratamento de distúrbios do sono.
Os distúrbios do sono, como a apneia do sono, a narcolepsia ou a insónia, são distúrbios médicos nos quais o doente tem dificuldade em manter o sono ou em iniciar o sono. Este transtorno provoca funções mentais, físicas, sociais e emocionais irregulares. Os distúrbios do sono são tratados através de diferentes opções de tratamento de acordo com os sintomas dos doentes. A maioria dos doentes com apneia do sono são tratados através de terapias mecânicas.
O aumento dos distúrbios do sono aumentará a procura de opções de tratamento para os distúrbios do sono. Assim, espera-se que o aumento do stress mental devido à vida agitada e aos hábitos pouco saudáveis impulsione o crescimento do mercado de tratamento de distúrbios do sono. A extensão dos efeitos secundários pode ser fatal, causando medo do consumo nos doentes, o que leva a uma diminuição das vendas e da procura. Desta forma, os efeitos adversos dos medicamentos atuam como um fator restritivo ao crescimento do mercado de tratamento de distúrbios do sono. O crescente avanço tecnológico está a atuar como uma oportunidade para aumentar a procura do mercado de tratamento de distúrbios do sono. O elevado custo do tratamento dos distúrbios do sono representa um desafio para o crescimento do mercado do tratamento dos distúrbios do sono.
O relatório de mercado de tratamento de distúrbios do sono fornece detalhes sobre a quota de mercado, novos desenvolvimentos e análise de pipeline de produtos, impacto dos participantes do mercado doméstico e localizado, analisa as oportunidades em termos de bolsas de receitas emergentes, mudanças nas regulamentações de mercado , aprovações de produtos, decisões estratégicas, lançamentos de produtos , expansões geográficas e inovações tecnológicas no mercado. Para compreender a análise e o cenário do mercado de tratamento de distúrbios do sono, contacte a Data Bridge Market Research para um briefing de analista.
Âmbito e dimensão do mercado de tratamento de distúrbios do sono
O mercado de tratamento de distúrbios do sono está categorizado em sete segmentos notáveis que se baseiam no tipo, tratamento, via de administração, tipo de medicamento, tipo de população, utilizador final e canal de distribuição. O crescimento entre segmentos ajuda-o a analisar os nichos de crescimento e as estratégias para abordar o mercado e determinar as suas principais áreas de aplicação e a diferença nos seus mercados-alvo.
- Com base no tipo, o mercado de tratamento de distúrbios do sono está segmentado em insónia, apneia do sono, síndrome das pernas inquietas (SPI), narcolepsia e outros. Em 2021, espera-se que o segmento da insónia domine o mercado de tratamento de distúrbios do sono devido ao avanço tecnológico para desenvolver opções de tratamento inovadoras para este distúrbio específico.
- Com base no tratamento, o mercado de tratamento de distúrbios do sono está segmentado em terapia farmacológica, terapia mecânica, dispositivos de avanço mandibular, estimulador do nervo hipoglosso, cirurgia e outros. Em 2021, prevê-se que o segmento da terapia farmacológica domine o mercado de tratamento de distúrbios do sono porque estão disponíveis diversas classes de medicamentos para o tratamento de distúrbios do sono de acordo com os sintomas dos doentes.
- Com base na via de administração, o mercado de tratamento das perturbações do sono está segmentado em oral, parentérica e outras. Em 2021, prevê-se que o segmento oral domine o mercado de tratamento de distúrbios do sono devido à maior disponibilidade de medicamentos orais para o tratamento de distúrbios do sono, como a narcolepsia, a síndrome das pernas inquietas (SPI) e a insónia, entre outros.
- Com base no tipo de medicamento, o mercado de tratamento para distúrbios do sono está segmentado em medicamentos de marca e genéricos. Em 2021, prevê-se que o segmento dos genéricos domine o mercado de tratamento de distúrbios do sono devido à maior disponibilidade de medicamentos genéricos para o tratamento de distúrbios do sono, como a gabapentina , comprimidos de zolpidem ER e comprimidos de eszopiclona, CIV , entre outros.
- Com base no tipo de população, o mercado de tratamento de distúrbios do sono está segmentado em crianças e adultos. Em 2021, prevê-se que o segmento de adultos domine o mercado de tratamento de distúrbios do sono devido ao aumento da população geriátrica em todo o mundo, exigindo opções de tratamento mais avançadas.
- Com base no utilizador final, o mercado de tratamento de distúrbios do sono está segmentado em hospitais, clínicas especializadas, assistência médica domiciliária, centro de cirurgia ambulatória e outros. Em 2021, espera-se que o segmento hospitalar domine o mercado de tratamento de distúrbios do sono devido à capacidade financeira dos hospitais de comprar equipamentos caros usados em cirurgias, além da presença de profissionais treinados para operar os dispositivos mecânicos e os medicamentos prescritos .
- Com base no canal de distribuição, o mercado de tratamento de distúrbios do sono está segmentado em licitação direta, farmácia hospitalar, farmácia de retalho, farmácia online e outros. Em 2021, prevê-se que o segmento de licitação direta domine o mercado de tratamento de distúrbios do sono, uma vez que a maioria dos medicamentos é adquirida através de serviços de licitação direta.
Análise do mercado de tratamento de distúrbios do sono no Médio Oriente e em África a nível de país
O mercado de tratamento de distúrbios do sono no Médio Oriente e em África é analisado e são fornecidas informações sobre o tamanho do mercado por país, tipo, tratamento, via de administração, tipo de medicamento, tipo de população, utilizador final e canal de distribuição, conforme acima referenciado.
Os países abrangidos pelo relatório de mercado sobre o tratamento das perturbações do sono no Médio Oriente e em África são a África do Sul, a Arábia Saudita, os Emirados Árabes Unidos, o Egito, o Kuwait, Israel e o resto do Médio Oriente e África.
A Arábia Saudita domina o mercado de tratamento de distúrbios do sono no Médio Oriente e em África devido aos avanços tecnológicos no país, juntamente com a presença de grandes empresas de tratamento de distúrbios do sono na região.
A secção do relatório sobre os países também fornece fatores individuais que impactam o mercado e alterações na regulamentação do mercado nacional que impactam as tendências atuais e futuras do mercado. Pontos de dados como novas vendas, vendas de reposição, demografia do país, atos regulamentares e tarifas de importação e exportação são alguns dos principais indicadores utilizados para prever o cenário de mercado para países individuais. Além disso, a presença e a disponibilidade de marcas do Médio Oriente e de África e os desafios enfrentados devido à grande ou escassa concorrência das marcas locais e nacionais, bem como o impacto dos canais de venda, são considerados quando se fornece uma análise de previsão dos dados do país.
Os lançamentos de novos produtos pelos fabricantes estão a criar novas oportunidades para os participantes do mercado de tratamento de distúrbios do sono
O mercado de tratamento de distúrbios do sono também fornece uma análise detalhada do mercado para o crescimento de cada país na indústria estética com vendas no mercado de tratamento de distúrbios do sono, impacto do avanço no mercado de tratamento de distúrbios do sono e mudanças nos cenários regulamentares com o seu suporte ao mercado de tratamento de distúrbios do sono. Os dados estão disponíveis para o período histórico de 2011 a 2019.
Análise do cenário competitivo e da quota de mercado no tratamento das perturbações do sono
O panorama competitivo do mercado de tratamento de distúrbios do sono fornece detalhes por concorrente. Os detalhes incluídos são a visão geral da empresa, finanças da empresa, receitas geradas, potencial de mercado, investimento em investigação e desenvolvimento, novas iniciativas de mercado, localizações e instalações de produção, pontos fortes e fracos da empresa, lançamento de produtos, pipelines de testes de produto, aprovações de produto, patentes, largura e amplitude do produto, domínio da aplicação, curva de vida da tecnologia. Os pontos de dados fornecidos acima estão apenas relacionados com o foco da empresa no mercado de tratamento de distúrbios do sono.
Os principais participantes abordados no relatório de mercado de tratamento de distúrbios do sono no Médio Oriente e África são a Jazz Pharmaceuticals, Inc., a Pfizer Inc., a Viatris Inc., a Hikma Pharmaceuticals PLC, a Taj Pharmaceuticals Limited, a Mallinckrodt, a Alembic Pharmaceuticals Limited, a Dr. Reddy's Laboratories Ltd. , Koninklijke Philips NV, ResMed entre outros players nacionais. Os analistas do DBMR compreendem os pontos fortes competitivos e fornecem análises competitivas para cada concorrente em separado.
Muitos lançamentos de produtos e acordos são também iniciados por empresas de todo o mundo, o que está também a acelerar o mercado de tratamento de distúrbios do sono.
Por exemplo,
- Em setembro de 2020, a Jazz Pharmaceuticals, Inc. anunciou a colaboração com o conteúdo educativo sobre saúde do sono da American Heart Association para fortalecer a sua área terapêutica de saúde do sono. Esta nova colaboração feita pela empresa aumentou a sua credibilidade no mercado.
A colaboração, as joint ventures e outras estratégias do participante do mercado estão a aumentar o mercado da empresa no tratamento de distúrbios do sono, o que também traz o benefício para a organização melhorar a sua oferta de tratamento de distúrbios do sono.
SKU-
Obtenha acesso online ao relatório sobre a primeira nuvem de inteligência de mercado do mundo
- Painel interativo de análise de dados
- Painel de análise da empresa para oportunidades de elevado potencial de crescimento
- Acesso de analista de pesquisa para personalização e customização. consultas
- Análise da concorrência com painel interativo
- Últimas notícias, atualizações e atualizações Análise de tendências
- Aproveite o poder da análise de benchmark para um rastreio abrangente da concorrência
Índice
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 TYPE LIFELINE CURVE
2.8 DBMR MARKET POSITION GRID
2.9 VENDOR SHARE ANALYSIS
2.1 MARKET END USER COVERAGE GRID
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
5 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: REGULATIONS
6 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 RISING PREVALENCE OF SLEEPING DISORDERS
7.1.2 RISE IN THE GERIATRIC POPULATION
7.1.3 INCREASE IN MENTAL STRESS DUE TO HECTIC LIFE & UNHEALTHY HABITS
7.1.4 LARGE POOL OF UNDIAGNOSED SLEEP APNEA PATIENTS
7.1.5 PRESENCE OF POTENTIAL CLINICAL PIPELINE CANDIDATES
7.2 RESTRAINTS
7.2.1 SIDE EFFECTS ASSOCIATED WITH THESE DRUGS
7.2.2 PATENT EXPIRATION OF MAJOR SLEEP DISORDER TREATMENT DRUGS
7.2.3 EMERGENCE OF GENERICS
7.3 OPPORTUNITIES
7.3.1 TECHNOLOGICAL ADVANCEMENTS IN THE SLEEP AIDS
7.3.2 INCREASING USAGE OF SOCIAL MEDIA AND GROWING ADDICTION OF GADGETS SUCH AS SMARTPHONES AND LAPTOPS
7.3.3 GROWING AWARENESS ABOUT TARGET DISEASE
7.4 CHALLENGES
7.4.1 HIGH COST OF DIAGNOSIS & TREATMENT FOR SLEEPING DISORDER
7.4.2 STRINGENT REGULATORY LANDSCAPE
7.4.3 POTENTIAL ILL-EFFECTS DUE TO DRUG ABUSE
8 IMPACT OF COVID-19 ON MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES BY MARKET PLAYERS DURING COVID-19
8.5 CONCLUSION
9 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TYPE
9.1 OVERVIEW
9.2 INSOMNIA
9.2.1 INSOMNIA
9.2.2 CHILD INSOMNIA
9.2.3 OTHERS
9.3 SLEEP APNEA
9.3.1 OBSTRUCTIVE SLEEP APNEA
9.3.2 CENTRAL SLEEP APNEA
9.3.3 SNORING
9.3.4 INFANT SLEEP APNEA
9.3.5 OTHERS
9.4 RESTLESS LEGS SYNDROME (RLS)
9.5 NARCOLEPSY
9.5.1 TYPE 1
9.5.2 TYPE 2
10 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT
10.1 OVERVIEW
10.2 PHARMACOLOGICAL THERAPY
10.2.1 CANNABIDIOL
10.2.2 ANTI-PARKINSONIAN DRUGS (DOPAMINE AGONISTS)
10.2.3 BENZODIAZEPINES
10.2.4 NON-BENZODIAZEPINE
10.2.5 MELATONIN RECEPTOR STIMULATOR
10.2.6 STIMULANTS
10.2.7 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) OR SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIS)
10.2.8 TRICYCLIC ANTIDEPRESSANTS
10.2.9 SODIUM OXYBATE (XYREM)
10.2.10 OTHERS
10.3 MECHANICAL THERAPY
10.3.1 CPAP (CONTINUOUS POSITIVE AIRWAY PRESSURE)
10.3.2 BI-LEVEL PAP
10.3.3 AUTO CPAP OR AUTO BI-LEVEL PAP
10.3.4 ADAPTIVE SERVO-VENTILATION (ASV)
10.4 MANDIBULAR ADVANCEMENT DEVICES
10.5 HYPOGLOSSAL NERVE STIMULATOR
10.6 SURGERY
10.6.1 SOMNOPLASTY
10.6.2 TONSILLECTOMY
10.6.3 NASAL SURGERY
10.6.4 OTHERS
10.7 OTHERS
11 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION
11.1 OVERVIEW
11.2 ORAL
11.2.1 TABLET
11.2.2 PILLS
11.2.3 OTHERS
11.3 PARENTERAL
11.4 OTHERS
12 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE
12.1 OVERVIEW
12.2 GENERICS
12.3 BRANDED
12.3.1 XYREM
12.3.2 EFFEXOR XR
12.3.3 AMBIEN
12.3.4 PRISTIQ
12.3.5 ZENZEDI
12.3.6 VYVANSE
12.3.7 OTHERS
13 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE
13.1 OVERVIEW
13.2 ADULT
13.3 CHILDREN
14 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 AMBULATORY SURGICAL CENTER
14.6 OTHERS
15 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 HOSPITAL PHARMACY
15.4 RETAIL PHARMACY
15.5 ONLINE PHARMACY
15.6 OTHERS
16 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY GEOGRAPHY
16.1 MIDDLE EAST AND AFRICA
16.1.1 SOUTH AFRICA
16.1.2 SOUTH ARABIA
16.1.3 UAE
16.1.4 EGYPT
16.1.5 KUWAIT
16.1.6 ISRAEL
16.1.7 REST OF MIDDLE EAST AND AFRICA
17 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
18 SWOT ANALYSIS
19 COMPANY PROFILE
19.1 JAZZ PHARMACEUTICALS, INC.
19.1.1 COMPANY SNAPSHOT
19.1.2 REVENUE ANALYSIS
19.1.3 COMPANY SHARE ANALYSIS
19.1.4 PRODUCT PORTFOLIO
19.1.5 RECENT DEVELOPMENTS
19.2 PFIZER INC.
19.2.1 COMPANY SNAPSHOT
19.2.2 REVENUE ANALYSIS
19.2.3 COMPANY SHARE ANALYSIS
19.2.4 PRODUCT PORTFOLIO
19.2.5 RECENT DEVELOPMENT
19.3 ELI LILLY AND COMPANY
19.3.1 COMPANY SNAPSHOT
19.3.2 REVENUE ANALYSIS
19.3.3 COMPANY SHARE ANALYSIS
19.3.4 PRODUCT PORTFOLIO
19.3.5 RECENT DEVELOPMENTS
19.4 VIATRIS INC.
19.4.1 COMPANY SNAPSHOT
19.4.2 REVENUE ANALYSIS
19.4.3 COMPANY SHARE ANALYSIS
19.4.4 PRODUCT PORTFOLIO
19.4.5 RECENT DEVELOPMENTS
19.5 RESMED
19.5.1 COMPANY SNAPSHOT
19.5.2 REVENUE ANALYSIS
19.5.3 PRODUCT PORTFOLIO
19.5.4 RECENT DEVELOPMENTS
19.6 MALLINCKRODT
19.6.1 COMPANY SNAPSHOT
19.6.2 REVENUE ANALYSIS
19.6.3 PRODUCT PORTFOLIO
19.6.4 RECENT DEVELOPMENT
19.7 KONINKLIJKE PHILIPS N.V.
19.7.1 COMPANY SNAPSHOT
19.7.2 REVENUE ANALYSIS
19.7.3 PRODUCT PORTFOLIO
19.7.4 RECENT DEVELOPMENTS
19.8 ALEMBIC PHARMACEUTICALS LIMITED
19.8.1 COMPANY SNAPSHOT
19.8.2 REVENUE ANALYSIS
19.8.3 PRODUCT PORTFOLIO
19.8.4 RECENT DEVELOPMENT
19.9 AMNEAL PHARMACEUTICALS LLC
19.9.1 COMPANY SNAPSHOT
19.9.2 REVENUE ANALYSIS
19.9.3 PRODUCT PORTFOLIO
19.9.4 RECENT DEVELOPMENTS
19.1 APOTEX INC.
19.10.1 COMPANY SNAPSHOT
19.10.2 PRODUCT PORTFOLIO
19.10.3 RECENT DEVELOPMENT
19.11 ARBOR PHARMACEUTICALS
19.11.1 COMPANY SNAPSHOT
19.11.2 PRODUCT PORTFOLIO
19.11.3 RECENT DEVELOPMENTS
19.12 AUROBINDO PHARMA USA (A SUBSIDIARY OF AUROBINDO PHARMA)
19.12.1 COMPANY SNAPSHOT
19.12.2 REVENUE ANALYSIS
19.12.3 PRODUCT PORTFOLIO
19.12.4 RECENT DEVELOPMENTS
19.13 BMC MEDICAL CO.
19.13.1 COMPANY SNAPSHOT
19.13.2 PRODUCT PORTFOLIO
19.13.3 RECENT DEVELOPMENT
19.14 DEVILBISS HEALTHCARE LLC
19.14.1 COMPANY SNAPSHOT
19.14.2 PRODUCT PORTFOLIO
19.14.3 RECENT DEVELOPMENT
19.15 DR. REDDY’S LABORATORIES LTD.
19.15.1 COMPANY SNAPSHOT
19.15.2 REVENUE ANALYSIS
19.15.3 PRODUCT PORTFOLIO
19.15.4 RECENT DEVELOPMENT
19.16 HIKMA PHARMACEUTICALS PLC
19.16.1 COMPANY SNAPSHOT
19.16.2 REVENUE ANALYSIS
19.16.3 PRODUCT PORTFOLIO
19.16.4 RECENT DEVELOPMENTS
19.17 LUPIN PHARMACEUTICALS, INC. (A SUBSIDIARY OF LUPIN)
19.17.1 COMPANY SNAPSHOT
19.17.2 REVENUE ANALYSIS
19.17.3 PRODUCT PORTFOLIO
19.17.4 RECENT DEVELOPMENTS
19.18 OVENTUS
19.18.1 COMPANY SNAPSHOT
19.18.2 REVENUE ANALYSIS
19.18.3 PRODUCT PORTFOLIO
19.18.4 RECENT DEVELOPMENTS
19.19 SANOFI-AVENTIS U.S. LLC (A SUBSIDIARY OF SANOFI)
19.19.1 COMPANY SNAPSHOT
19.19.2 REVENUE ANALYSIS
19.19.3 PRODUCT PORTFOLIO
19.19.4 RECENT DEVELOPMENTS
19.2 SOMNOMED
19.20.1 COMPANY SNAPSHOT
19.20.2 REVENUE ANALYSIS
19.20.3 PRODUCT PORTFOLIO
19.20.4 RECENT DEVELOPMENTS
19.21 TAJ PHARMACEUTICALS LIMITED
19.21.1 COMPANY SNAPSHOT
19.21.2 PRODUCT PORTFOLIO
19.21.3 RECENT DEVELOPMENT
19.22 TARO PHARMACEUTICAL INDUSTRIES LTD.
19.22.1 COMPANY SNAPSHOT
19.22.2 REVENUE ANALYSIS
19.22.3 PRODUCT PORTFOLIO
19.22.4 RECENT DEVELOPMENT
19.23 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
19.23.1 COMPANY SNAPSHOT
19.23.2 REVENUE ANALYSIS
19.23.3 PRODUCT PORTFOLIO
19.23.4 RECENT DEVELOPMENTS
20 QUESTIONNAIRE
21 RELATED REPORTS
Lista de Tabela
LIST OF TABLES
TABLE 1 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: PIPELINE ANALYSIS
TABLE 2 GENERIC DRUGS FOR SLEEP DISORDER TREATMENT
TABLE 3 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2018-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 6 MIDDLE EAST AND AFRICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 7 MIDDLE EAST AND AFRICA SLEEP SPNEA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 8 MIDDLE EAST AND AFRICA RESTLESS LEGS SYNDROME (RLS) IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 9 MIDDLE EAST AND AFRICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 10 MIDDLE EAST AND AFRICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 11 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT, 2018-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 13 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 14 MIDDLE EAST AND AFRICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 15 MIDDLE EAST AND AFRICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 16 MIDDLE EAST AND AFRICA MANDIBULAR ADVANCEMENT DEVICES IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 17 MIDDLE EAST AND AFRICA HYPOGLOSSAL NERVE STIMULATOR IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 18 MIDDLE EAST AND AFRICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 19 MIDDLE EAST AND AFRICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 20 MIDDLE EAST AND AFRICA OTHERS IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 21 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 24 MIDDLE EAST AND AFRICA PARENTERAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 25 MIDDLE EAST AND AFRICA OTHERS PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 26 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA GENERICS PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 28 MIDDLE EAST AND AFRICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 30 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE, 2018-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA ADULT IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 32 MIDDLE EAST AND AFRICA CHILDREN IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 33 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY END USER, 2018-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA HOSPITALS IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 35 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 36 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 37 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTER IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 38 MIDDLE EAST AND AFRICA OTHERS IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 39 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA DIRECT TENDER IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 41 MIDDLE EAST AND AFRICA HOSPITAL PHARMACY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 42 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 43 MIDDLE EAST AND AFRICA ONLINE PHARMACY IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 44 MIDDLE EAST AND AFRICA HOSPITALS IN SLEEP DISORDER TREATMENT MARKET, BY TYPE 2019-2028 (USD MILLION) BY REGION
TABLE 45 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 54 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)
TABLE 61 SOUTH AFRICA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 62 SOUTH AFRICA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 63 SOUTH AFRICA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)
TABLE 64 SOUTH AFRICA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)
TABLE 65 SOUTH AFRICA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 66 SOUTH AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 67 SOUTH AFRICA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 68 SOUTH AFRICA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 69 SOUTH AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 70 SOUTH AFRICA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 71 SOUTH AFRICA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 72 SOUTH AFRICA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 73 SOUTH AFRICA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)
TABLE 76 SAUDI ARABIA SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 84 SAUDI ARABIA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 85 SAUDI ARABIA ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 86 SAUDI ARABIA PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 87 SAUDI ARABIA BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 88 SAUDI ARABIA SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)
TABLE 89 SAUDI ARABIA SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)
TABLE 90 SAUDI ARABIA SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)
TABLE 91 UAE SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 UAE INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 UAE SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)
TABLE 94 UAE NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)
TABLE 95 UAE SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 96 UAE PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 97 UAE MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 98 UAE SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 99 UAE PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 100 UAE ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 101 UAE PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 102 UAE BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 103 UAE SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)
TABLE 104 UAE SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)
TABLE 105 UAE SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)
TABLE 106 EGYPT SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 EGYPT INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 EGYPT SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)
TABLE 109 EGYPT NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)
TABLE 110 EGYPT SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 111 EGYPT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 112 EGYPT MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 113 EGYPT SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 114 EGYPT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 115 EGYPT ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 116 EGYPT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 117 EGYPT BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 118 EGYPT SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)
TABLE 119 EGYPT SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)
TABLE 120 EGYPT SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)
TABLE 121 KUWAIT SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 122 KUWAIT INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 123 KUWAIT SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)
TABLE 124 KUWAIT NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)
TABLE 125 KUWAIT SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 126 KUWAIT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 127 KUWAIT MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 128 KUWAIT SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 129 KUWAIT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 130 KUWAIT ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 131 KUWAIT PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 132 KUWAIT BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 133 KUWAIT SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)
TABLE 134 KUWAIT SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)
TABLE 135 KUWAIT SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)
TABLE 136 ISRAEL SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 ISRAEL INSOMNIA IN SLEEP DISORDER TREATMENT MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 ISRAEL SLEEP APNEA IN SLEEP DISORDER TREATMENT MARKET , BY TYPE 2020-2028 (USD MILLION)
TABLE 139 ISRAEL NARCOLEPSY IN SLEEP DISORDER TREATMENT MARKET ,2020-2028 (USD MILLION)
TABLE 140 ISRAEL SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 141 ISRAEL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 142 ISRAEL MECHANICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 143 ISRAEL SURGERY IN SLEEP DISORDER TREATMENT MARKET, BY TREATMENT 2020-2028 (USD MILLION)
TABLE 144 ISRAEL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 145 ISRAEL ORAL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 2020-2028 (USD MILLION)
TABLE 146 ISRAEL PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 147 ISRAEL BRANDED PHARMACOLOGICAL THERAPY IN SLEEP DISORDER TREATMENT MARKET, BY DRUGS TYPE 2020-2028 (USD MILLION)
TABLE 148 ISRAEL SLEEP DISORDER TREATMENT MARKET, BY POPULATION TYPE 2020-2028 (USD MILLION)
TABLE 149 ISRAEL SLEEP DISORDER TREATMENT MARKET, BY END USER 2020-2028 (USD MILLION)
TABLE 150 ISRAEL SLEEP DISORDER TREATMENT MARKET, BY DISTRIBUTION CHANNEL 2020-2028 (USD MILLION)
TABLE 151 REST OF MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET , BY TYPE 2019-2028 (USD MILLION)
Lista de Figura
LIST OF FIGURES
FIGURE 1 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 9 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: MARKET END USER COVERAGE GRID
FIGURE 10 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: SEGMENTATION
FIGURE 11 RISING PREVALENCE OF SLEEPING DISORDERS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 INSOMNIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET IN 2021 & 2028
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET
FIGURE 14 PROPORTION OF AMERICAN TWEENS (8- TO 12- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)
FIGURE 15 PROPORTION OF AMERICAN TEENS (13- TO 18- YEAR-OLD) SPENDING TIME WITH SCREEN MEDIA IN A DAY (IN HOURS)
FIGURE 16 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020
FIGURE 17 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 18 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 19 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020
FIGURE 21 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, 2020-2028 (USD MILLION)
FIGURE 22 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, CAGR (2020-2028)
FIGURE 23 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 25 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 26 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 27 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020
FIGURE 29 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, 2020-2028 (USD MILLION)
FIGURE 30 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, CAGR (2020-2028)
FIGURE 31 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DRUGS TYPE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020
FIGURE 33 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 34 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, CAGR (2020-2028)
FIGURE 35 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020
FIGURE 37 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY END USER, 2020-2028 (USD MILLION)
FIGURE 38 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY END USER, CAGR (2020-2028)
FIGURE 39 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 41 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 42 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 43 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: SNAPSHOT (2020)
FIGURE 45 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020)
FIGURE 46 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: BY TYPE (2020-2028)
FIGURE 49 MIDDLE EAST AND AFRICA SLEEP DISORDER TREATMENT MARKET: COMPANY SHARE 2020 (%)
Metodologia de Investigação
A recolha de dados e a análise do ano base são feitas através de módulos de recolha de dados com amostras grandes. A etapa inclui a obtenção de informações de mercado ou dados relacionados através de diversas fontes e estratégias. Inclui examinar e planear antecipadamente todos os dados adquiridos no passado. Da mesma forma, envolve o exame de inconsistências de informação observadas em diferentes fontes de informação. Os dados de mercado são analisados e estimados utilizando modelos estatísticos e coerentes de mercado. Além disso, a análise da quota de mercado e a análise das principais tendências são os principais fatores de sucesso no relatório de mercado. Para saber mais, solicite uma chamada de analista ou abra a sua consulta.
A principal metodologia de investigação utilizada pela equipa de investigação do DBMR é a triangulação de dados que envolve a mineração de dados, a análise do impacto das variáveis de dados no mercado e a validação primária (especialista do setor). Os modelos de dados incluem grelha de posicionamento de fornecedores, análise da linha de tempo do mercado, visão geral e guia de mercado, grelha de posicionamento da empresa, análise de patentes, análise de preços, análise da quota de mercado da empresa, normas de medição, análise global versus regional e de participação dos fornecedores. Para saber mais sobre a metodologia de investigação, faça uma consulta para falar com os nossos especialistas do setor.
Personalização disponível
A Data Bridge Market Research é líder em investigação formativa avançada. Orgulhamo-nos de servir os nossos clientes novos e existentes com dados e análises que correspondem e atendem aos seus objetivos. O relatório pode ser personalizado para incluir análise de tendências de preços de marcas-alvo, compreensão do mercado para países adicionais (solicite a lista de países), dados de resultados de ensaios clínicos, revisão de literatura, mercado remodelado e análise de base de produtos . A análise de mercado dos concorrentes-alvo pode ser analisada desde análises baseadas em tecnologia até estratégias de carteira de mercado. Podemos adicionar quantos concorrentes necessitar de dados no formato e estilo de dados que procura. A nossa equipa de analistas também pode fornecer dados em tabelas dinâmicas de ficheiros Excel em bruto (livro de factos) ou pode ajudá-lo a criar apresentações a partir dos conjuntos de dados disponíveis no relatório.
